Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6
Therapeutics and Clinical Risk Management
- View all (1820)
- Volume 15, 2019 (129)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Archive: Volume 4, 2008
Erratum
Rapidis A, Sarlis N, Lefebvre J-L, et al
Therapeutics and Clinical Risk Management 2008, 4:1381-1381
Published Date: 5 December 2008
A thyrotoxicosis outbreak due to dietary pills in Paris
Vincent Ioos, Vincent Das, Eric Maury, Jean-Luc Baudel, Jérôme Guéchot, et al
Therapeutics and Clinical Risk Management 2008, 4:1375-1379
Published Date: 5 December 2008
Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients
Dimitrios Chantzichristos, Andréasson Björn, Johansson Peter
Therapeutics and Clinical Risk Management 2008, 4:1371-1374
Published Date: 5 December 2008
Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
Thérèse H Franco, Ahmed Khan, Vishal Joshi, Beje Thomas
Therapeutics and Clinical Risk Management 2008, 4:1367-1370
Published Date: 5 December 2008
Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy
Tamana Walia, J Fernando Quevedo, Timothy J Hobday, Gary Croghan, Aminah Jatoi
Therapeutics and Clinical Risk Management 2008, 4:1363-1366
Published Date: 5 December 2008
Evaluation of cardiotoxicity five years after 2D planned, non-simulated, radiation therapy for left breast cancer
Kyriaki Pistevou-Gompaki, Apostolos Hatzitolios, Nikos Eleftheriadis, Evaggelos Boultoukas, George Ntaios, et al
Therapeutics and Clinical Risk Management 2008, 4:1359-1362
Published Date: 5 December 2008
Effects of treatment with antimicrobial agents on the human colonic microflora
Fatemeh Rafii, John B Sutherland, Carl E Cerniglia
Therapeutics and Clinical Risk Management 2008, 4:1343-1357
Published Date: 5 December 2008
Newer treatments for fibromyalgia syndrome
Richard E Harris, Daniel J Clauw
Therapeutics and Clinical Risk Management 2008, 4:1331-1342
Published Date: 5 December 2008
Tadalafil in the treatment of erectile dysfunction
Robert M Coward, Culley C Carson
Therapeutics and Clinical Risk Management 2008, 4:1315-1329
Published Date: 5 December 2008
Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno
Therapeutics and Clinical Risk Management 2008, 4:1305-1313
Published Date: 5 December 2008
Exemestane in early breast cancer: a review
Michael Untch, Christian Jackisch
Therapeutics and Clinical Risk Management 2008, 4:1295-1304
Published Date: 5 December 2008
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate
PH Chandrasekar
Therapeutics and Clinical Risk Management 2008, 4:1285-1294
Published Date: 5 December 2008
Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients
Leo Flamholc, Magnus Gisslén
Therapeutics and Clinical Risk Management 2008, 4:1281-1284
Published Date: 5 December 2008
Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?
Rafael Zaragoza, Javier Pemán, Miguel Salavert, Ángel Viudes, Amparo Solé, et al
Therapeutics and Clinical Risk Management 2008, 4:1261-1280
Published Date: 5 December 2008
Treatment of grass pollen allergy: focus on a standardized grass allergen extract – Grazax®
Moisés Calderón, Tove Brandt
Therapeutics and Clinical Risk Management 2008, 4:1255-1260
Published Date: 5 December 2008
Vinflunine in the treatment of bladder cancer
Mark Bachner, Maria De Santis
Therapeutics and Clinical Risk Management 2008, 4:1243-1253
Published Date: 5 December 2008
Bazedoxifene for the prevention of postmenopausal osteoporosis
Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Giuseppe Martini, Ranuccio Nuti
Therapeutics and Clinical Risk Management 2008, 4:1229-1242
Published Date: 5 December 2008
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
Daanish Hoda, George R Simon, Christopher R Garrett
Therapeutics and Clinical Risk Management 2008, 4:1221-1227
Published Date: 5 December 2008
Febuxostat in the management of hyperuricemia and chronic gout: a review
Miao Hu, Brian Tomlinson
Therapeutics and Clinical Risk Management 2008, 4:1209-1220
Published Date: 5 December 2008
Mometasone furoate in the management of asthma: a review
Ricardo A Tan, Jonathan Corren
Therapeutics and Clinical Risk Management 2008, 4:1201-1208
Published Date: 5 December 2008
Impact of PPIs on patient focused symptomatology in GERD
ABR Thomson
Therapeutics and Clinical Risk Management 2008, 4:1185-1200
Published Date: 5 December 2008
Recombinant human growth hormone in the treatment of Turner syndrome
Bessie E Spiliotis
Therapeutics and Clinical Risk Management 2008, 4:1177-1183
Published Date: 5 December 2008
Treatment of severe psoriasis with infliximab
JA Leman, AD Burden
Therapeutics and Clinical Risk Management 2008, 4:1165-1175
Published Date: 5 December 2008
Gemcitabine and taxanes in metastatic breast cancer: a systematic review
Vinay Gudena, Alberto J Montero, Stefan Glück
Therapeutics and Clinical Risk Management 2008, 4:1157-1164
Published Date: 5 December 2008
Tolvaptan and its potential in the treatment of hyponatremia
Megan B Dixon, Y Howard Lien
Therapeutics and Clinical Risk Management 2008, 4:1149-1155
Published Date: 5 December 2008